|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||107.45 - 108.40|
|52 Week Range||93.13 - 126.70|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||35.76|
|Forward Dividend & Yield||2.79 (2.57%)|
|Ex-Dividend Date||Feb. 25, 2021|
|1y Target Est||N/A|
Yahoo Finance’s Anjalee Khemlani reports the latest developments on the coronavirus vaccines.
AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.
AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application for a full-fledged license to sell the shot, the Wall Street Journal reported on Friday. Asked about the Wall Street Journal report, AstraZeneca did not comment directly, saying in an emailed statement that it "continues to progress our FDA submission for AZD1222." Last week, AstraZeneca said it was working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval.